Status:
UNKNOWN
N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation.
Lead Sponsor:
moshe yeshurun
Conditions:
Mucositis
Transplant-Related Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Oral mucositis (OM) is a major source of morbidity in patients undergoing hematopoietic cell transplantation (HCT). N-acetyl cysteine (NAC) is an antioxidant, widely used as mucolytic agent or antidot...
Eligibility Criteria
Inclusion
- Patients with multiple myeloma and lymphoma in partial response and complete remission.
- Undergoing high-dose chemotherapy with autologous transplantation.
Exclusion
- • Known sensitivity to NAC
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2023
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT04756622
Start Date
April 1 2021
End Date
March 31 2023
Last Update
February 16 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.